<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00903747</url>
  </required_header>
  <id_info>
    <org_study_id>M0001-C102</org_study_id>
    <nct_id>NCT00903747</nct_id>
  </id_info>
  <brief_title>Thorough Corrected QT Interval (QTc) Study To Evaluate Possible Effects of Prucalopride on ECG Parameters</brief_title>
  <official_title>A Phase I Thorough QT/QTc Study To Evaluate The Effect of Therapeutic and Supratherapeutic Multiple Doses of Prucalopride on Cardiac Repolarisation in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Movetis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Movetis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-arm, parallel-group active- and placebo-controlled, double-blind randomised&#xD;
      study, stratified by gender and with a hybrid crossover group design, to compare treatment&#xD;
      with prucalopride 2 mg/day (intended therapeutic dose) and prucalopride 10 mg/day&#xD;
      (supratherapeutic dose) with placebo. A single oral dose of 400 mg moxifloxacin is included&#xD;
      as a positive control in terms of the effect on cardiac repolarisation.&#xD;
&#xD;
      Study hypothesis:&#xD;
&#xD;
      Treatment with therapeutic (2 mg) or supratherapeutic (10 mg) doses of prucalopride in&#xD;
      healthy male and female volunteers will not increase QTc interval compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total number of 120 healthy subjects (with an approximate 1:1 female:male ratio) are&#xD;
      planned to be randomised.&#xD;
&#xD;
      Day 1: a baseline ECG profile. Day 1: Group 1 will receive prucalopride, Group 2a will&#xD;
      receive moxifloxacin, and Group 2b will receive placebo.&#xD;
&#xD;
      On Day 5 (steady-state level is reached), a full ECG assessment day will be performed,&#xD;
      enabling the comparison of prucalopride 2 mg with placebo.&#xD;
&#xD;
      Subsequently, the number of tablets will be escalated in all groups (blinded) with 1 tablet a&#xD;
      day up to 5 tablets.&#xD;
&#xD;
      On Day 13 (steady state for the supratherapeutic dose level of 10 mg of prucalopride) another&#xD;
      ECG assessment day will be performed, enabling a comparison of prucalopride 10 mg with&#xD;
      placebo.&#xD;
&#xD;
      Group 2b will receive a single dose of moxifloxacin on Day 15. All subjects will be&#xD;
      discharged on Day 16. Subjects will remain in the CRU throughout the treatment period.&#xD;
&#xD;
      All subjects will return for a follow-up visit on Day 30 (± 1 week) (approximately 14 days&#xD;
      after the last dose).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment with therapeutic (2 mg) or supratherapeutic (10 mg) doses of prucalopride in healthy male and female volunteers does not increase QTc interval compared to placebo.</measure>
    <time_frame>January to April 2009</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prucalopride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo/moxifloxacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prucalopride</intervention_name>
    <description>2-10 mg prucalopride</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Resolor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
    <description>400 mg moxifloxacin (Group 2a)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo (Group 2b)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Healthy volunteers aged between 18 to 50 years.&#xD;
&#xD;
          2. Body mass index (BMI) between 18 and 30 kg/m2.&#xD;
&#xD;
          3. Female subjects must:&#xD;
&#xD;
               -  be of childbearing potential with a negative serum β-human chorionic gonadotropin&#xD;
                  (β-HCG) test at screening, and be willing and able to use medically acceptable&#xD;
                  double barrier methods of birth control, throughout the whole study; or&#xD;
&#xD;
               -  be postmenopausal; or&#xD;
&#xD;
               -  have received surgical sterilisation at least 6 months before screening; AND&#xD;
&#xD;
               -  females must not be receiving hormone replacement therapy (HRT).&#xD;
&#xD;
        Main exclusion Criteria:&#xD;
&#xD;
          1. Abnormal QTcF and/or heart rate/blood pressure values at baseline.&#xD;
&#xD;
          2. Subjects with ECG abnormalities that may interfere with the accurate assessment of the&#xD;
             QT interval.&#xD;
&#xD;
          3. Subjects with known cardiovascular disorders.&#xD;
&#xD;
          4. Subjects with known clinically significant arrhythmias.&#xD;
&#xD;
          5. Subjects with risk factors e.g., Torsades de Pointes.&#xD;
&#xD;
          6. Subjects with clinically relevant, abnormal serum electrolytes or complete blood count&#xD;
             (CBC) at screening.&#xD;
&#xD;
          7. Female subjects who are lactating or pregnant.&#xD;
&#xD;
          8. Subjects suffering from other significant medical conditions.&#xD;
&#xD;
          9. Subjects with a known allergy or sensitivity to moxifloxacin, or to prucalopride.&#xD;
&#xD;
         10. Subjects with a positive screening test for hepatitis B, hepatitis C, or HIV at&#xD;
             screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Remi VD Broeck, MD</last_name>
    <role>Study Director</role>
    <affiliation>Movetis NV</affiliation>
  </overall_official>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>May 15, 2009</study_first_submitted>
  <study_first_submitted_qc>May 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2009</study_first_posted>
  <last_update_submitted>May 15, 2009</last_update_submitted>
  <last_update_submitted_qc>May 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Remi Van Den Broeck</name_title>
    <organization>Movetis NV</organization>
  </responsible_party>
  <keyword>Prucalopride</keyword>
  <keyword>safety study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Prucalopride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

